Research Paper Volume 14, Issue 23 pp 9617—9631
A circadian rhythm-related biomarker for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
Figure 2. Assessment of predictive capability of the newly-established biomarker. (A–C) Three-year AUCs were 0.701, 0.688 and 0.691 in the discovery cohort, the validation cohort and GSE30219, respectively. (D–F) PCA analysis revealed that the low-risk group was apparently separated from its counterpart in dimensionality 1. (G–I) The hazard was linked to unwanted prognosis and high expression levels of four genes (BARX2, DDIT4, INHA, S100P) in the discovery cohort, the validation cohort and GSE30219.